A previous report indicated that DDR1 inhibitors were currently under clinical testing for multiple indications (merestinib against metastatic breast cancer [NCT03292536], merestinib against HR+ or HER2– breast cancers [NCT02791334]) [51]. Here, ERBB2 is linked to breast carcinoma.